News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Galip Can Uyar: The Phase 3 CONTACT-02 Trial
Collage photo of Galip Can Uyar and Neeraj Agarwal
Jul 2, 2025, 09:11

Galip Can Uyar: The Phase 3 CONTACT-02 Trial

Galip Can Uyar, Medical Doctor at Etlik City Hospital, shared a post on X about a paper by Neeraj Agarwal et al. published in The Lancet Oncology:

“BREAKING in mCRPC
Published in The Lancet Oncology (July 2025)
The phase 3 CONTACT-02 trial shows:
Cabozantinib + Atezolizumab significantly improves PFS over second ARPI (6.3 vs 4.2 months; HR: 0.65, p=0.0007)
But no OS benefit was observed (14.8 vs 15.0 months; HR: 0.89)
ORR: 13% vs 6%, DCR: 72% vs 53%
A novel AR-independent combo, especially promising for patients with poor prognosis extrapelvic soft tissue metastases.”

Title: Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial

Authors: Neeraj Agarwal, Arun A Azad, Joan Carles, Nobuaki Matsubara, Stéphane Oudard, Fred Saad, Axel S Merseburger, Andrey Soares, Bradley A McGregor, Bogdan Zurawski, Marinos Tsiatas, Scott North, Igor Bondarenko, Margarita Alfie, Evangelos Bournakis, Lorenzo Antonuzzo, Lena Evilevitch, Andrew Simmons, Fong Wang, Roberta Ferraldeschi, Prachi Nandoskar, Sumanta K Pal.

You can read the Full Article in The Lancet Oncology.

Galip Can Uyar: The Phase 3 CONTACT-02 Trial

More posts featuring Galip Can Uyar.

Andrew Simmons Andrey Soares Arun A. Azad atezolizumab Axel S. Merseburger Bogdan Zurawski Bradley A. McGregor Cabozantinib cancer CONTACT-02 Evangelos Bournakis Fong Wang Fred Saad Galip Can Uyar Igor Bondarenko Joan Carles Lena Evilevitch Lorenzo Antonuzzo Margarita Alfie Marinos Tsiatas mCRPC Neeraj Agarwal Nobuaki Matsubara OncoDaily Oncology Prachi Nandoskar prostate cancer Roberta Ferraldeschi Scott North Stephane Oudard Sumanta K. Pal The Lancet Oncology
Special Coverage
Oncolibrary
Jul 2, 2025, 14:00
ESMO GI 2025 Highlights: OrigAMI-1 Trial on Amivantamab Rechallenge in mCRC
Blog
Jul 2, 2025, 13:41
Kenji López-Cuevas Congratulates Andreas Charalambous on His Appointment as Chairman of the SPCC
Blog
Jul 2, 2025, 13:25
Julie Ince-Demetriou: On 7th July Inaugural Pink Sky Grants Scheme Will Open to EOI Applications
Blog
Jul 2, 2025, 13:19
Korede Akindele: Sarcoma May Be Rare But Survival Shouldn’t Be
Blog
Jul 2, 2025, 13:08
Irini Agapidaki on the Critical Role of Prevention and the National Program 'Prolamvano'
Blog
Jul 2, 2025, 12:57
Mehmet Murat Zerey: I am Starting a New Position as an Advanced Genitourinary Oncology Clinical Fellow at Vanderbilt University Medical Center
Insight
Jul 2, 2025, 12:37
Wafaa M Rashed: New on the PAPERI Blog - Epigenetics and Maternal Nutrition in Africa as a Public Health Priority
Blog
Jul 2, 2025, 12:32
Sergio Cifuentes Canaval: What it Means to Build a Career in Oncology From Latin America
Blog
Jul 2, 2025, 12:21
We Managed to Give Unforgettable Moments to Girls and Boys of the Hospital Infantil of Mexico 'Federico Gómez' - Cancer Warriors Foundation of Mexico
Blog
Jul 2, 2025, 11:46
Lucrecia Ruiz: I’m Starting a New Position as Head of the Melanoma, Head and Neck Cancer, and Neuro-Oncology Section at MD Anderson Madrid
Oncolibrary
Jul 2, 2025, 11:40
ESMO GI 2025 Highlights: BXCL701 + Pembrolizumab in Second-Line Advanced PDAC
Blog
Jul 2, 2025, 11:38
Memorial Sloan Kettering Cancer Center Congratulates Its Awardees